Pharmaceuticals (Jun 2024)

Pharmacological Activation of SIRT3 Modulates the Response of Cancer Cells to Acidic pH

  • Michele Aventaggiato,
  • Tania Arcangeli,
  • Enza Vernucci,
  • Federica Barreca,
  • Luigi Sansone,
  • Laura Pellegrini,
  • Elena Pontemezzo,
  • Sergio Valente,
  • Rossella Fioravanti,
  • Matteo Antonio Russo,
  • Antonello Mai,
  • Marco Tafani

DOI
https://doi.org/10.3390/ph17060810
Journal volume & issue
Vol. 17, no. 6
p. 810

Abstract

Read online

Cancer cells modulate their metabolism, creating an acidic microenvironment that, in turn, can favor tumor progression and chemotherapy resistance. Tumor cells adopt strategies to survive a drop in extracellular pH (pHe). In the present manuscript, we investigated the contribution of mitochondrial sirtuin 3 (SIRT3) to the adaptation and survival of cancer cells to a low pHe. SIRT3-overexpressing and silenced breast cancer cells MDA-MB-231 and human embryonic kidney HEK293 cells were grown in buffered and unbuffered media at pH 7.4 and 6.8 for different times. mRNA expression of SIRT3 and CAVB, was measured by RT-PCR. Protein expression of SIRT3, CAVB and autophagy proteins was estimated by western blot. SIRT3-CAVB interaction was determined by immunoprecipitation and proximity ligation assays (PLA). Induction of autophagy was studied by western blot and TEM. SIRT3 overexpression increases the survival of both cell lines. Moreover, we demonstrated that SIRT3 controls intracellular pH (pHi) through the regulation of mitochondrial carbonic anhydrase VB (CAVB). Interestingly, we obtained similar results by using MC2791, a new SIRT3 activator. Our results point to the possibility of modulating SIRT3 to decrease the response and resistance of tumor cells to the acidic microenvironment and ameliorate the effectiveness of anticancer therapy.

Keywords